Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Davide Busato"'
Autor:
Davide Busato, Sara Capolla, Paolo Durigutto, Monica Mossenta, Sara Bozzer, Daniele Sblattero, Paolo Macor, Michele Dal Bo, Giuseppe Toffoli
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a very low survival rate at 5 years. The use of chemotherapeutic agents results in only modest prolongation of survival and is generally associated
Externí odkaz:
https://doaj.org/article/da4516817faf461f9882e4337173d4b5
Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models
Autor:
Sara Capolla, Monica Argenziano, Sara Bozzer, Tiziana D’Agaro, Tamara Bittolo, Luigina De Leo, Tarcisio Not, Davide Busato, Michele Dal Bo, Giuseppe Toffoli, Roberta Cavalli, Valter Gattei, Riccardo Bomben, Paolo Macor
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionMicroRNAs represent interesting targets for new therapies because their altered expression influences tumor development and progression. miR-17 is a prototype of onco-miRNA, known to be overexpressed in B-cell non-Hodgkin lymphoma (B-NHL)
Externí odkaz:
https://doaj.org/article/700fa76819c64673b3c87d0dc34aa22c
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 18, p 10279 (2022)
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all pancreatic cancers, with a 5-year survival rate of 7% and 80% of patients diagnosed with advanced or metastatic malignancies. Despite recent advances in diagnostic testing, surgical tech
Externí odkaz:
https://doaj.org/article/45f856c9f5ed4b3c922270a46cd10d65
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 17, p 10038 (2022)
Hepatocellular carcinoma (HCC) is the second most lethal tumor, with a 5-year survival rate of 18%. Early stage HCC is potentially treatable by therapies with curative intent, whereas chemoembolization/radioembolization and systemic therapies are the
Externí odkaz:
https://doaj.org/article/f73bd2f1e71b41a2888e9d78a8f1b5ea
Autor:
Luca Bedon, Michele Dal Bo, Monica Mossenta, Davide Busato, Giuseppe Toffoli, Maurizio Polano
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 3, p 1075 (2021)
Although extensive advancements have been made in treatment against hepatocellular carcinoma (HCC), the prognosis of HCC patients remains unsatisfied. It is now clearly established that extensive epigenetic changes act as a driver in human tumors. Th
Externí odkaz:
https://doaj.org/article/78b575ad1d0640f69e3e0138432ced87
Publikováno v:
Cancers, Vol 12, Iss 6, p 1668 (2020)
Hepatocellular carcinoma (HCC) metabolism is redirected to glycolysis to enhance the production of metabolic compounds employed by cancer cells to produce proteins, lipids, and nucleotides in order to maintain a high proliferative rate. This mechanis
Externí odkaz:
https://doaj.org/article/af85eef15ab640df9f0ea5c515fbea46
Autor:
Monica Mossenta, Davide Busato, Lorena Baboci, Federica Di Cintio, Giuseppe Toffoli, Michele Dal Bo
Publikováno v:
Cancers, Vol 11, Iss 8, p 1086 (2019)
Hepatocellular carcinoma (HCC) is a malignancy characterized by neoangiogenesis that is determined by an augmented production of proangiogenesis factors by tumor and adjacent cells. This unbalanced angiogenesis process is a key feature of HCC carcino
Externí odkaz:
https://doaj.org/article/9757999a1c7844a59ccc6f2298949c07
Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models
Autor:
Sara Capolla, Monica Argenziano, Sara Bozzer, Tiziana D’Agaro, Tamara Bittolo, Luigina Leo, Tarcisio Not, Davide Busato, Michele Bo, Giuseppe Toffoli, Roberta Cavalli, Valter Gattei, Riccardo Bomben, Paolo Macor
Background: MicroRNAs represent interesting targets for new therapies because their altered expression influences tumor development and progression. miR-17 is a prototype of onco-miRNA, known to be overexpressed in B-cell non-Hodgkin lymphoma (B-NHL)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74a6f85464a8de92834836f655d726d9
https://doi.org/10.21203/rs.3.rs-2277122/v1
https://doi.org/10.21203/rs.3.rs-2277122/v1
Publikováno v:
International Journal of Molecular Sciences. 23:10038
Hepatocellular carcinoma (HCC) is the second most lethal tumor, with a 5-year survival rate of 18%. Early stage HCC is potentially treatable by therapies with curative intent, whereas chemoembolization/radioembolization and systemic therapies are the
Autor:
Michele Dal Bo, Davide Busato, Federica Di Cintio, Monica Mossenta, Lorena Baboci, Giuseppe Toffoli
Publikováno v:
Expert Review of Clinical Pharmacology. 12:453-470
The introduction of immune checkpoint inhibitors has been lately proposed for the treatment of hepatocellular carcinoma (HCC) with respect to other cancer types. Several immunotherapeutic approaches are now under evaluation for HCC treatment includin